Cimicoxib
Names | |
---|---|
Preferred IUPAC name
4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzene-1-sulfonamide | |
Identifiers | |
3D model (
JSmol ) |
|
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard
|
100.170.774 |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C16H13ClFN3O3S | |
Molar mass | 381.81 g·mol−1 |
Pharmacology | |
QM01AH93 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Cimicoxib (UR-8880 trade name Cimalgex) is a
COX-2 inhibitor
.
Synthesis
Reaction of the imine with TosMIC in the presence of potassium carbonate leads to what may be viewed as 2+3 cycloaddition of the nitrogen analogue of a ketene to form the imidazole ring.
References
- ^ "European Public Assessment Report: Cimalgex (cimicoxib)". European Medicines Agency. 17 September 2018.
- PMID 12877584.